Physician

Mark D Gelernt, MD

According to 2025 Medicare claims, Mark Gelernt, MD (NPI: 1972556207) practices cardiology in the Vineland, NJ market, with the plurality of this provider's patient population coming from Cumberland, NJ. This provider's primary affiliated billing organization is CARDIOVASCULAR ASSOCIATES OF THE DELAWARE VALLEY,P A (NPI: 1366495632; TIN: 223321233) and primary practice location at 08360-6931.

Gelernt's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 2,183 traditional Medicare patients, billed 7,149 HCPCS/CPT codes, and received $748,311 in Medicare payments. The top billing code was 93306 (Ultrasound of heart with color-depicted blood flow, rate, direction and valve function). Part D data shows 6,589 prescription claims across 960 beneficiaries totaling $1,739,339 in drug costs, led by Xarelto (Rivaroxaban). 2023 DME data shows 12 claims. Open Payments data shows 114 records totaling $61,236. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $393,036 to $748,311. Similarly, Part D prescription costs have moved sharply higher in recent years, from $274,470 to $1,739,339. In contrast, DME billing represents a smaller volume and declined steadily, from $48,801 to $12,342.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	2,563	6,943	$393,036
2016	2,592	8,093	$456,387
2017	2,734	7,605	$470,482
2018	3,016	7,553	$482,857
2019	2,559	6,342	$444,357
2020	2,385	6,703	$693,692
2021	2,785	7,413	$674,228
2022	2,285	6,107	$573,613
2023	2,097	6,773	$807,037
2024	2,183	7,149	$748,311

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	426	2,549	$274,470
2016	446	2,834	$385,044
2017	474	2,893	$551,972
2018	478	3,311	$535,571
2019	530	3,606	$882,649
2020	651	4,347	$936,223
2021	708	4,617	$1,130,742
2022	703	4,784	$1,388,249
2023	830	5,560	$1,632,043
2024	960	6,589	$1,739,339

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	107	$137,782
2016	N/R	234	$105,999
2017	N/R	218	$52,634
2018	N/R	34	$590
2019	N/R	109	$10,712
2020	N/R	210	$24,111
2021	N/R	146	$34,742
2022	N/R	146	$9,744
2023	N/R	12	$164
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	566	572	$121
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	576	841	$104
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	449	627	$14
93000	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report	628	971	$12
93010	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only	730	863	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xarelto	Rivaroxaban	446	32,526	$573,977
Eliquis	Apixaban	215	14,473	$276,248
Entresto	Sacubitril/Valsartan	154	11,878	$251,839
Repatha Sureclick	Evolocumab	117	8,092	$151,434
Farxiga	Dapagliflozin Propanediol	114	8,380	$146,342

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	109	$1,872	Impulse Dynamics (USA) Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	5	$59,364	Novartis Pharmaceuticals Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mark D. Gelernt, MD?

Tedicare shows public-source Medicare data for Mark D. Gelernt, MD (NPI 1972556207), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark D. Gelernt, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Mark D. Gelernt, MD?

Mark D. Gelernt, MD is linked to CARDIOVASCULAR ASSOCIATES OF THE DELAWARE VALLEY,P A (billing NPI 1366495632) in the available physician profile data.

Does Mark D. Gelernt, MD have Open Payments data?

Mark D. Gelernt, MD has 114 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.